Document is current
Any future updates will be listed below
-
Authors
Castro, Elena
Wang, Di
Walsh, Sarah
Craigie, Samantha
Haltner, Anja
Nazari, Jonathan
Niyazov, Alexander
Samjoo, Imtiaz A. https://orcid.org/0000-0003-1415-8055
-
Funding
Funding for this research was provided by:
This work was sponsored by Pfizer Inc. EC was a paid consultant to Pfizer in connection with the development of this manuscript.
This work was sponsored by Pfizer Inc. DW is an employee of EVERSANA™, which was a paid consultant to Pfizer in connection with the development of this manuscript.
This work was sponsored by Pfizer Inc. SW is an employee of EVERSANA™, which was a paid consultant to Pfizer in connection with the development of this manuscript.
This work was sponsored by Pfizer Inc. SC is an employee of EVERSANA™, which was a paid consultant to Pfizer in connection with the development of this manuscript.
This work was sponsored by Pfizer Inc. AH is an employee of EVERSANA™, which was a paid consultant to Pfizer in connection with the development of this manuscript.
This work was sponsored by Pfizer Inc. JN was an employee of Pfizer Inc. during the development of this manuscript.
This work was sponsored by Pfizer Inc. AN is an employee of Pfizer Inc. during the development of this manuscript.
- License Information
-
More Information
Article History
Received: 1 May 2024
Revised: 4 November 2024
Accepted: 14 November 2024
First Online: 7 December 2024
Competing interests
: EC is supported by a Senior Clinician-Scientist grant from Asociación Española Contra el Cancer (AECC). EC is a consultant for Pfizer and has consulting or advisory roles for AstraZeneca, Bayer, Daiichi-Sankyo, Janssen, Merck, MSD Oncology, Novartis, and Pfizer; has received research funding from AstraZeneca, Bayer, Janssen and Pfizer and has received travel support from AstraZeneca, Bayer, Janssen and Pfizer. AN is an employee of Pfizer and owns Pfizer stock. JN is supported by the 2021-2023 University of Illinois at Chicago-Pfizer Fellowship. IAS, DW, SW, SC, and AH are employees of EVERSANA, Canada and USA, which was a paid consultant to Pfizer in connection with the development of this manuscript.
